Clinical Trials Browser

Active not recruiting × INDUSTRY × Urologic Neoplasms × Clear all

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT05544552 2026-01-12

SURF301

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Active not recruiting

367 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT03288545 2025-11-10

EV-103

Phase 1/2 Active not recruiting

348 enrolled 1 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT04544748 2024-03-06

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

Phase 1 Active not recruiting

48 enrolled

DermatologicGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urologic Neoplasms

Clinical Trials

Savolitinib vs. Sunitinib in MET-driven PRCC.

SURF301

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

EV-103

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies